Bacil Pharma (524516) Q1 24/25 earnings summary

Executive summary

• Board approved and adopted unaudited financial results for the quarter ended 30th June 2024, with the meeting held on 14th August 2024.

• Statutory auditor provided an unmodified review opinion on the financial results.

Financial highlights

• Revenue from operations for the quarter was ₹1.08 lakh, down from ₹4.76 lakh in the same quarter last year and ₹2.12 lakh in the previous quarter.

• Total expenses for the quarter were ₹4.47 lakh, compared to ₹3.02 lakh in the same quarter last year and ₹6.16 lakh in the previous quarter.

• Loss before tax was ₹3.39 lakh, compared to a profit of ₹1.74 lakh in the same quarter last year and a loss of ₹4.05 lakh in the previous quarter.

• Profit for the period, after other comprehensive income, was ₹21.25 lakh, compared to ₹20.07 lakh in the same quarter last year and a loss of ₹3.05 lakh in the previous quarter.

• Basic and diluted EPS for the quarter were both ₹(0.06), compared to ₹0.03 in the same quarter last year and ₹(0.07) in the previous quarter.

Outlook and guidance

• No forward-looking guidance or outlook was provided.